Cheng Qinglu, Gibb Michelle, Graves Nicholas, Finlayson Kathleen, Pacella Rosana E
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
Wound Specialist Services, Brisbane, Queensland, Australia.
BMC Health Serv Res. 2018 Jun 7;18(1):421. doi: 10.1186/s12913-018-3234-3.
Venous leg ulcers (VLUs) are expensive to treat and impair quality of life of affected individuals. Although improved healing and reduced recurrence rates have been observed following the introduction of evidence-based guidelines, a significant evidence-practice gap exists. Compression is the recommended first-line therapy for treatment of VLUs but unlike many other developed countries, the Australian health system does not subsidise compression therapy. The objective of this study is to estimate the cost-effectiveness of guideline-based care for VLUs that includes public sector reimbursement for compression therapy for affected individuals in Australia.
A Markov model was designed to simulate the progression of VLU for patients receiving guideline-based optimal prevention and treatment, with reimbursement for compression therapy, and then compared to usual care in each State and Territory in Australia. Model inputs were derived from published literature, expert opinion, and government documents. The primary outcomes were changes to costs and health outcomes from a decision to implement guideline-based optimal care compared with the continuation of usual care. Sensitivity analyses were performed to test the robustness of model results.
Guideline-based optimal care incurred lower total costs and improved quality of life of patients in all States and Territories in Australia regardless of the health service provider. We estimated that providing compression therapy products to affected individuals would cost the health system an additional AUD 270 million over 5 years but would result in cost savings of about AUD 1.4 billion to the health system over the same period. An evaluation of unfavourable values for key model parameters revealed a wide margin of confidence to support the findings.
This study shows that guideline-based optimal care would be a cost-effective and cost-saving strategy to manage VLUs in Australia. Results from this study support wider adoption of guideline-based care for VLUs and the reimbursement of compression therapy. Other countries that face similar issues may benefit from investing in guideline-based wound care.
下肢静脉溃疡(VLU)的治疗成本高昂,会影响患者的生活质量。尽管引入循证指南后已观察到愈合情况有所改善且复发率降低,但仍存在显著的证据与实践差距。压力治疗是推荐用于治疗VLU的一线疗法,但与许多其他发达国家不同,澳大利亚医疗系统不补贴压力治疗。本研究的目的是评估基于指南的VLU护理的成本效益,该护理包括为澳大利亚受影响个体的压力治疗提供公共部门报销。
设计了一个马尔可夫模型,以模拟接受基于指南的最佳预防和治疗(包括压力治疗报销)的患者的VLU进展情况,然后与澳大利亚每个州和领地的常规护理进行比较。模型输入来自已发表的文献、专家意见和政府文件。主要结果是与继续常规护理相比,实施基于指南的最佳护理决策所导致的成本和健康结果的变化。进行了敏感性分析以测试模型结果的稳健性。
无论医疗服务提供者如何,基于指南的最佳护理在澳大利亚所有州和领地都降低了总成本并改善了患者的生活质量。我们估计,在5年内为受影响个体提供压力治疗产品将使医疗系统额外花费2.7亿澳元,但同期将为医疗系统节省约14亿澳元。对关键模型参数的不利值进行评估后发现,有很大的置信区间支持这些结果。
本研究表明,基于指南的最佳护理将是澳大利亚管理VLU的具有成本效益且节省成本的策略。本研究结果支持更广泛地采用基于指南的VLU护理以及压力治疗报销。面临类似问题的其他国家可能会从投资基于指南的伤口护理中受益。